Therapy News and Research

RSS

Positive results from NanoString's second clinical study of PAM50-based breast cancer assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature.

From NanoString Technologies 7 Dec 2012

Ketogenic diet and fasting can reduce seizures in children

Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small Johns Hopkins Children's Center study.

7 Dec 2012

Kessler Foundation to study effects of intellectual enrichment on cognitive decline in people with MS

The National Multiple Sclerosis (MS) Society awarded Victoria Leavitt, Ph.D., a $44,000 grant to study the effects of intellectual enrichment on cognitive decline in individual with multiple sclerosis.

7 Dec 2012

Roundup: Fla. judge rules legislature must decide on prison care privatization; Skepticism over Ore. medical liability reform proposal

A Tallahassee judge ruled Tuesday that a legislative committee did not have the authority to approve a contract regarding prison health care services. According to Businessweek, the plan would privatize health care services in three of Florida's four prison system regions. Circuit Judge John Cooper, who made the decision, said the policy changes must be approved by the full Legislature, rather than just a panel of 14 select legislators.

6 Dec 2012

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Electrotherapy not effective pain treatment in the aftermath of pancreatic surgery

Osteopathy may help reduce chronic pain and stiffness after thoracic surgery. However, electrotherapy is not effective pain treatment in the aftermath of pancreatic surgery. These are the findings of a thesis from Sahlgrenska Academy, University of Gothenburg, Sweden, that studied complementary and alternative therapies.

6 Dec 2012

UC San Diego Health System receives Comprehensive Stroke Center designation

UC San Diego Medical Center-Hillcrest is one of five facilities in the country, and the only center in San Diego County, to be recognized as one of the first Comprehensive Stroke Centers (CSC), the newest level of certification for advanced stroke care awarded by The Joint Commission.

6 Dec 2012

Targeted therapy as common as chemotherapy at end of life

Targeted therapies are used as often as chemotherapy at the end of advanced cancer patients' lives, according to study results using US data.

6 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

Spine Revitalizer develops infographic about non-surgical back pain treatment

More than 3 in 4 Americans experience back pain at some point in their life. Thankfully, Spine Revitalizer has released a helpful resource to give basic information for those suffering from back pain.

6 Dec 2012

Maryland P3 Program can improve outcomes of patients with chronic diseases

A new program guide, published by the Centers for Disease Control and Prevention (CDC), features the Maryland Patients, Pharmacists, Partnerships (P3) as an effective model of how health care teams that include pharmacists can improve the outcomes of patients with chronic diseases.

6 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

Scientists evaluate two different strategies to treat Usher syndrome

After years of basic research, scientists at Johannes Gutenberg University Mainz (JGU) are increasingly able to understand the mechanisms underlying the human Usher syndrome and are coming ever closer to finding a successful treatment approach. The scientists in the Usher research group of Professor Dr. Uwe Wolfrum are evaluating two different strategies. These involve either the repair of mutated genes or the deactivation of the genetic defects using agents.

6 Dec 2012

Prescribing opioids lead to admissions for substance abuse treatment and deaths

A Viewpoint article published recently in the Journal of the American Medical Association suggests that the clinical practice of prescribing amphetamines, opioids, and benzodiazepines to treat chronic pain may be contributing to the increase in fatal drug overdoses and the likelihood that those drugs will be diverted to the illegal market.

6 Dec 2012

Tenofovir DF safe and effective in treating adolescents with HBV

A recent clinical trial found that the adult antiviral drug, tenofovir disoproxil fumarate (tenofovir DF), is safe and effective in treating adolescents with hepatitis B virus (HBV). Trial results published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), show that tenofovir DF suppressed HBV in 89% of pediatric participants.

6 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

Obesity ramps up thoracic surgery costs

Obese patients have significantly increased operating times when undergoing lobectomy for primary lung cancer, show US study results.

5 Dec 2012

Surprising discovery about physical properties of cancer cells

A surprising discovery about the physical properties of cancer cells could help improve a new diagnostic approach - a liquid biopsy - that detects, measures, and evaluates cancer cells in blood.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012